Recent Advances in Targeted Radionuclide Therapy of Cancers:@0.319158:0.035749:0.914575:0.035749:0.914575:0.019993:0.319158:0.019993:0.011680:0.012508:0.012450:0.012508:0.011738:0.006523:0.005330:0.014239:0.013181:0.010660:0.013143:0.011738:0.012450:0.012508:0.007466:0.005330:0.003848:0.011738:0.005330:0.007179:0.013143:0.005809:0.012950:0.012508:0.006523:0.012508:0.013181:0.005330:0.011680:0.013143:0.013181:0.003848:0.012604:0.011738:0.011699:0.012450:0.003848:0.003848:0.013181:0.012508:0.005330:0.008197:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.012604:0.006042:0.005330:0.015644:0.013143:0.011738:0.012450:0.012508:0.005792:0.007466
TREATMENT APPROACHES:@0.983689:0.278245:0.983689:0.065272:0.955679:0.065272:0.955679:0.278245:0.000000:0.000000:0.000000:0.057096:-0.123230:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.375913
29:@0.955522:0.038184:0.976595:0.038184:0.976595:0.018587:0.955522:0.018587:0.010536:0.010536
HANDBOOK OF ONCOLOGY:@0.679047:0.970015:0.915156:0.970015:0.915156:0.956010:0.679047:0.956010:0.011682:0.012657:0.012657:0.012726:0.009818:0.014864:0.014864:0.010109:0.004738:0.014864:0.008296:0.004738:0.014864:0.012657:0.013906:0.014864:0.007902:0.014864:0.014915:0.010126
the placebo group. Radium-223 compared :@0.084242:0.096166:0.480495:0.096166:0.480495:0.080410:0.084242:0.080410:0.006331:0.011545:0.012315:0.003387:0.012931:0.003656:0.012950:0.012257:0.012315:0.012931:0.012411:0.003387:0.012758:0.005519:0.012411:0.011507:0.012931:0.005138:0.003387:0.011488:0.012950:0.012989:0.003656:0.011507:0.017857:0.006196:0.010468:0.010468:0.010468:0.003387:0.012257:0.012411:0.017857:0.012931:0.012950:0.005519:0.012315:0.013183:0.005330
with placebo significantly prolonged time :@0.084242:0.112517:0.480474:0.112517:0.480474:0.096761:0.084242:0.096761:0.015798:0.003656:0.006331:0.011545:0.008076:0.012931:0.003656:0.012950:0.012257:0.012315:0.012931:0.012411:0.008078:0.007274:0.003656:0.012758:0.011545:0.003656:0.004589:0.004589:0.012257:0.012950:0.011545:0.006331:0.003656:0.010122:0.008076:0.012931:0.005519:0.012411:0.003656:0.012411:0.011545:0.012758:0.012315:0.012989:0.008078:0.006331:0.003656:0.017857:0.012504:0.005330
to first symptomatic SRE.:@0.084242:0.128868:0.307512:0.128868:0.307512:0.113112:0.084242:0.113112:0.006523:0.012604:0.005330:0.004686:0.004686:0.005792:0.007466:0.006523:0.005330:0.007466:0.010314:0.018049:0.013123:0.006523:0.012604:0.018049:0.013143:0.006523:0.003848:0.012450:0.005330:0.009583:0.011680:0.010314:0.005330
12:@0.307494:0.123260:0.319924:0.123260:0.319924:0.114075:0.307494:0.114075:0.006215:0.006215
The most frequent side effects of Ra-:@0.102424:0.145236:0.475163:0.145236:0.475163:0.129480:0.102424:0.129480:0.008197:0.011738:0.012508:0.010891:0.018049:0.012604:0.007466:0.006523:0.010891:0.006042:0.005713:0.012508:0.013123:0.011699:0.012508:0.011738:0.006523:0.010891:0.007466:0.003848:0.013181:0.012508:0.010891:0.012508:0.006096:0.006042:0.012508:0.012450:0.006523:0.007466:0.010891:0.012604:0.006042:0.010891:0.011680:0.013143:0.006388
dium-223 therapy are diarrhoea, nausea, :@0.084240:0.161587:0.480482:0.161587:0.480482:0.145832:0.084240:0.145832:0.013181:0.003848:0.011699:0.018049:0.006388:0.010660:0.010660:0.010660:0.007158:0.006523:0.011738:0.012508:0.005792:0.013133:0.013123:0.010314:0.007158:0.013143:0.005715:0.012508:0.007149:0.013181:0.003848:0.013143:0.005792:0.006344:0.011738:0.012604:0.012508:0.013143:0.005330:0.007147:0.011738:0.013143:0.011699:0.007466:0.012508:0.013143:0.005330:0.005330
vomiting and thrombocytopaenia. Prior :@0.084240:0.177939:0.480510:0.177939:0.480510:0.162183:0.084240:0.162183:0.010660:0.012604:0.018049:0.003848:0.006523:0.003848:0.011738:0.012950:0.012719:0.013143:0.011738:0.013181:0.012719:0.006523:0.011738:0.005707:0.012604:0.018049:0.013123:0.012604:0.012450:0.010314:0.006523:0.012604:0.013123:0.013143:0.012508:0.011738:0.003848:0.013143:0.005330:0.012719:0.011392:0.005792:0.003848:0.012604:0.005792:0.005330
use  of  chemotherapy  or  external beam :@0.084240:0.194290:0.480485:0.194290:0.480485:0.178534:0.084240:0.178534:0.011699:0.007466:0.012508:0.005330:0.004512:0.012604:0.006042:0.005330:0.004508:0.012450:0.011738:0.012508:0.018049:0.012594:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.004508:0.012604:0.005792:0.005330:0.004505:0.012508:0.009236:0.006523:0.012508:0.006188:0.011738:0.013143:0.003848:0.009852:0.013123:0.012508:0.013143:0.018049:0.005330
radiotherapy  is associated with  a  higher :@0.084240:0.210641:0.480499:0.210641:0.480499:0.194885:0.084240:0.194885:0.005792:0.013143:0.013181:0.003848:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.003812:0.003848:0.007466:0.009159:0.013143:0.007466:0.007466:0.012604:0.012450:0.003848:0.013143:0.006523:0.012508:0.013181:0.009159:0.015990:0.003848:0.006523:0.011738:0.005330:0.003818:0.013143:0.005330:0.003820:0.011738:0.003848:0.012950:0.011738:0.012508:0.005792:0.005330
risk of haematotoxicity.:@0.084240:0.226992:0.298697:0.226992:0.298697:0.211237:0.084240:0.211237:0.005792:0.003848:0.007466:0.009660:0.005330:0.012604:0.006042:0.005330:0.011738:0.013143:0.012508:0.018049:0.013143:0.006523:0.012604:0.006523:0.012604:0.009236:0.003848:0.012450:0.003848:0.006523:0.010314:0.005330
13:@0.298681:0.221401:0.311111:0.221401:0.311111:0.212216:0.298681:0.212216:0.006215:0.006215
Bisphosphonates:@0.102424:0.243377:0.258557:0.243377:0.258557:0.227621:0.102424:0.227621:0.011045:0.003848:0.007466:0.013123:0.011738:0.012604:0.007466:0.013123:0.011738:0.012604:0.011738:0.013143:0.006523:0.012508:0.007466
are:@0.287652:0.243377:0.319015:0.243377:0.319015:0.227621:0.287652:0.227621:0.013143:0.005713:0.012508
bone-seeking:@0.348109:0.243377:0.475148:0.243377:0.475148:0.227621:0.348109:0.227621:0.013123:0.012604:0.011738:0.012508:0.006388:0.007466:0.012508:0.012508:0.009660:0.003848:0.011738:0.012950
agents that inhibit bone-resorbing action :@0.084240:0.259728:0.480487:0.259728:0.480487:0.243972:0.084240:0.243972:0.013143:0.012950:0.012508:0.011738:0.006523:0.007466:0.007895:0.006523:0.011738:0.013143:0.006523:0.007893:0.003848:0.011738:0.011738:0.003848:0.013123:0.003848:0.006523:0.007909:0.013123:0.012604:0.011738:0.012508:0.006388:0.005705:0.012508:0.007466:0.012604:0.005792:0.013123:0.003848:0.011738:0.012950:0.007897:0.013143:0.012450:0.006523:0.003848:0.012604:0.011738:0.005330
of osteoclasts. They are commonly used :@0.084240:0.276080:0.480470:0.276080:0.480470:0.260324:0.084240:0.260324:0.012604:0.006042:0.009140:0.012604:0.007466:0.006523:0.012508:0.012594:0.012450:0.003848:0.013143:0.007466:0.006523:0.007466:0.005330:0.009140:0.008197:0.011738:0.012508:0.010314:0.009140:0.013143:0.005715:0.012508:0.009140:0.012450:0.012604:0.018049:0.018049:0.012604:0.011738:0.003848:0.010314:0.009140:0.011699:0.007466:0.012508:0.013181:0.005330
in the  treatment  of  bone  metastases. Bi-:@0.084240:0.292431:0.475159:0.292431:0.475159:0.276675:0.084240:0.276675:0.003848:0.011738:0.008563:0.006523:0.011738:0.012508:0.005330:0.003215:0.006523:0.005709:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005330:0.003217:0.012604:0.006042:0.005330:0.003219:0.013123:0.012604:0.011738:0.012508:0.005330:0.003217:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.007466:0.012508:0.007466:0.005330:0.008563:0.011045:0.003848:0.006388
sphosphonates  have  been  successfully :@0.084240:0.308782:0.480464:0.308782:0.480464:0.293026:0.084240:0.293026:0.007466:0.013123:0.011738:0.012604:0.007466:0.013123:0.011738:0.012604:0.011738:0.013143:0.006523:0.012508:0.007466:0.005330:0.009494:0.011738:0.013143:0.010660:0.012508:0.005330:0.009496:0.013123:0.012508:0.012508:0.011738:0.005330:0.009492:0.007466:0.011699:0.012450:0.012450:0.012508:0.007466:0.007466:0.006042:0.011699:0.003848:0.003848:0.010314:0.005330
labelled  to diagnostic and therapeutic :@0.084240:0.325133:0.480493:0.325133:0.480493:0.309377:0.084240:0.309377:0.003848:0.013143:0.013123:0.012508:0.003848:0.003848:0.012508:0.013181:0.005330:0.007210:0.006523:0.012604:0.012527:0.013181:0.003848:0.013143:0.012950:0.011738:0.012604:0.007466:0.006523:0.003848:0.012450:0.012527:0.013143:0.011738:0.013181:0.012527:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.012508:0.011699:0.006523:0.003848:0.012450:0.005330
radionuclides for theranostics of bone me-:@0.084240:0.341485:0.475159:0.341485:0.475159:0.325729:0.084240:0.325729:0.005792:0.013143:0.013181:0.003848:0.012604:0.011738:0.011699:0.012450:0.003848:0.003848:0.013181:0.012508:0.007466:0.004772:0.006042:0.012604:0.005792:0.004762:0.006523:0.011738:0.012508:0.005792:0.013143:0.011738:0.012604:0.007466:0.006523:0.003848:0.012450:0.007466:0.004757:0.012604:0.006042:0.004761:0.013123:0.012604:0.011738:0.012508:0.004761:0.018049:0.012508:0.006388
tastases. Of all the radio-labelled bispho-:@0.084240:0.357836:0.475150:0.357836:0.475150:0.342080:0.084240:0.342080:0.006523:0.013143:0.007466:0.006523:0.013143:0.007466:0.012508:0.007466:0.005330:0.007543:0.016722:0.006042:0.007543:0.013143:0.003848:0.003860:0.007543:0.006523:0.011738:0.012508:0.007531:0.005792:0.013143:0.013181:0.003848:0.012604:0.006388:0.003848:0.013143:0.013123:0.012508:0.003848:0.003848:0.012508:0.013181:0.007543:0.013123:0.003848:0.007466:0.013123:0.011738:0.012604:0.006388
sphonates, zoledronate appears to have :@0.084240:0.374187:0.480478:0.374187:0.480478:0.358431:0.084240:0.358431:0.007466:0.013123:0.011738:0.012604:0.011738:0.013143:0.006523:0.012508:0.007466:0.005330:0.007812:0.008178:0.012604:0.003848:0.012508:0.013181:0.005713:0.012604:0.011738:0.013143:0.006523:0.012508:0.007812:0.013143:0.013123:0.013123:0.012508:0.013143:0.005792:0.007466:0.007812:0.006523:0.012604:0.007812:0.011738:0.013143:0.010660:0.012508:0.005330
the greatest promise for widespread clini-:@0.084240:0.390538:0.475140:0.390538:0.475140:0.374782:0.084240:0.374782:0.006523:0.011738:0.012508:0.006448:0.012950:0.005709:0.012508:0.013143:0.006523:0.012508:0.007466:0.006523:0.006452:0.013123:0.005715:0.012604:0.018049:0.003848:0.007466:0.012508:0.006456:0.006042:0.012604:0.005792:0.006446:0.015990:0.003848:0.013181:0.012508:0.007466:0.013123:0.005723:0.012508:0.013143:0.013181:0.006456:0.012450:0.003848:0.003848:0.011738:0.003848:0.006388
cal application due to its high uptake in :@0.084240:0.406890:0.480476:0.406890:0.480476:0.391134:0.084240:0.391134:0.012450:0.013143:0.003848:0.008178:0.013143:0.013123:0.013123:0.003848:0.003848:0.012450:0.013143:0.006523:0.003848:0.012604:0.011738:0.008178:0.013181:0.011699:0.012508:0.008168:0.006523:0.012604:0.008165:0.003848:0.006523:0.007466:0.008178:0.011738:0.003848:0.012950:0.011738:0.008168:0.011699:0.013123:0.006523:0.013143:0.009660:0.012508:0.008168:0.003848:0.011738:0.005330
bone lesions.:@0.084240:0.423241:0.204351:0.423241:0.204351:0.407485:0.084240:0.407485:0.013123:0.012604:0.011738:0.012508:0.005330:0.003848:0.012508:0.007466:0.003848:0.012604:0.011738:0.007466:0.005330
14:@0.204348:0.417683:0.216778:0.417683:0.216778:0.408498:0.204348:0.408498:0.006215:0.006215
RADIOIMMUNOTHERAPY OF B-CELL :@0.084242:0.456663:0.481705:0.456663:0.481705:0.437066:0.084242:0.437066:0.013641:0.017404:0.016463:0.006585:0.019756:0.006585:0.021167:0.021167:0.015052:0.017404:0.019756:0.009878:0.015993:0.012230:0.013641:0.017404:0.013170:0.014581:0.006585:0.019756:0.011289:0.006585:0.013641:0.009878:0.018344:0.012230:0.010348:0.010348:0.006585
NON-HODGKIN’S LYMPHOMA:@0.084242:0.475952:0.418205:0.475952:0.418205:0.456356:0.084242:0.456356:0.017404:0.019756:0.017404:0.009878:0.015993:0.019756:0.016463:0.019756:0.014581:0.006585:0.017404:0.006585:0.012230:0.006585:0.010348:0.014581:0.021167:0.013170:0.015993:0.019756:0.021167:0.017404
B-cell  lymphomas  are  classified  as  either :@0.084242:0.494609:0.480490:0.494609:0.480490:0.478853:0.084242:0.478853:0.011045:0.006388:0.012450:0.012508:0.003848:0.003848:0.005330:0.003539:0.003848:0.010314:0.018049:0.013123:0.011738:0.012604:0.018049:0.013143:0.007466:0.005330:0.003533:0.013143:0.005715:0.012508:0.005330:0.003525:0.012450:0.003848:0.013143:0.007466:0.007466:0.003848:0.004686:0.004686:0.012508:0.013181:0.005330:0.003541:0.013143:0.007466:0.005330:0.003535:0.012508:0.003848:0.006523:0.011738:0.012508:0.005792:0.005330
aggressive or indolent. Diffuse large B-cell :@0.084242:0.510961:0.480476:0.510961:0.480476:0.495205:0.084242:0.495205:0.013143:0.012950:0.012950:0.005709:0.012508:0.007466:0.007466:0.003848:0.010660:0.012508:0.006342:0.012604:0.005792:0.006321:0.003848:0.011738:0.013181:0.012604:0.003848:0.012508:0.011738:0.006523:0.005330:0.006321:0.014316:0.003848:0.006106:0.006042:0.011699:0.007466:0.012508:0.006331:0.003848:0.013143:0.005813:0.012950:0.012508:0.006331:0.011045:0.006388:0.012450:0.012508:0.003848:0.003848:0.005330
lymphoma  typifies  aggressive  type  and :@0.084242:0.527312:0.480478:0.527312:0.480478:0.511556:0.084242:0.511556:0.003848:0.010314:0.018049:0.013123:0.011738:0.012604:0.018049:0.013143:0.005330:0.006456:0.006523:0.010314:0.013123:0.003848:0.004686:0.004686:0.012508:0.007466:0.005330:0.006454:0.013143:0.012950:0.012950:0.005709:0.012508:0.007466:0.007466:0.003848:0.010674:0.012508:0.005330:0.006450:0.006523:0.010314:0.013123:0.012508:0.005330:0.006452:0.013143:0.011738:0.013181:0.005330
responds favourably  to chemotherapy. :@0.084242:0.543663:0.480492:0.543663:0.480492:0.527907:0.084242:0.527907:0.005713:0.012508:0.007466:0.013123:0.012604:0.011738:0.013181:0.007466:0.013932:0.006042:0.013143:0.010660:0.012604:0.011699:0.005792:0.013143:0.013123:0.003848:0.010314:0.005330:0.008613:0.006523:0.012604:0.013932:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.005330
Indolent B-cell lymphoma has a poorer re-:@0.084242:0.560014:0.475156:0.560014:0.475156:0.544258:0.084242:0.544258:0.004349:0.011738:0.013181:0.012604:0.003848:0.012508:0.011738:0.006523:0.005163:0.011045:0.006388:0.012450:0.012508:0.003848:0.003848:0.005176:0.003848:0.010314:0.018049:0.013123:0.011738:0.012604:0.018049:0.013143:0.005176:0.011738:0.013143:0.007466:0.005176:0.013143:0.005176:0.013123:0.012604:0.012604:0.005707:0.012508:0.005792:0.005165:0.005713:0.012508:0.006388
sponse  to  chemotherapy,  often  relapses :@0.084242:0.576366:0.480478:0.576366:0.480478:0.560610:0.084242:0.560610:0.007466:0.013123:0.012604:0.011738:0.007466:0.012508:0.005330:0.003645:0.006523:0.012604:0.005330:0.003635:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.005330:0.003631:0.012604:0.006042:0.006523:0.012508:0.011738:0.005330:0.003637:0.005711:0.012508:0.003848:0.013143:0.013123:0.007466:0.012508:0.007466:0.005330
and may become refractory  to  re-treat-:@0.084242:0.592717:0.475167:0.592717:0.475167:0.576961:0.084242:0.576961:0.013143:0.011738:0.013181:0.008948:0.018049:0.013143:0.010314:0.008948:0.013123:0.012508:0.012450:0.012604:0.018049:0.012508:0.008948:0.005711:0.012508:0.006042:0.005792:0.013143:0.012450:0.006523:0.012604:0.005792:0.010314:0.005330:0.003600:0.006523:0.012604:0.005330:0.003606:0.005713:0.012508:0.006388:0.006523:0.005707:0.012508:0.013143:0.006523:0.006388
ment. Most B-cell lymphomas overexpress :@0.084242:0.609068:0.480465:0.609068:0.480465:0.593312:0.084242:0.593312:0.018049:0.012508:0.011738:0.006523:0.005330:0.006127:0.017684:0.012604:0.007466:0.006523:0.006138:0.011045:0.006388:0.012450:0.012508:0.003848:0.003848:0.006138:0.003848:0.010314:0.018049:0.013123:0.011738:0.012604:0.018049:0.013143:0.007466:0.006138:0.012604:0.010660:0.012508:0.005711:0.012508:0.009236:0.013123:0.005713:0.012508:0.007466:0.007466:0.005330
CD20  on the tumour-cell membrane. :@0.084242:0.625419:0.480513:0.625419:0.480513:0.609663:0.084242:0.609663:0.015644:0.014316:0.010660:0.010660:0.005330:0.011903:0.012604:0.011738:0.017222:0.006523:0.011738:0.012508:0.017222:0.006523:0.011699:0.018049:0.012604:0.011699:0.005792:0.006388:0.012450:0.012508:0.003848:0.003848:0.017222:0.018049:0.012508:0.018049:0.013123:0.005792:0.013143:0.011738:0.012508:0.005330:0.005330
Rituximab is a monoclonal antibody :@0.084242:0.641771:0.480470:0.641771:0.480470:0.626015:0.084242:0.626015:0.011680:0.003848:0.006523:0.011699:0.009236:0.003848:0.018049:0.013143:0.013123:0.019550:0.003848:0.007466:0.019550:0.013143:0.019550:0.018049:0.012604:0.011738:0.012604:0.012450:0.003848:0.012604:0.011738:0.013131:0.003848:0.019550:0.013143:0.011738:0.006523:0.003848:0.013123:0.012604:0.013181:0.010314:0.005330
(MAbs) against CD20. Treatment of CD20-:@0.084242:0.658122:0.475136:0.658122:0.475136:0.642366:0.084242:0.642366:0.007100:0.017684:0.014239:0.013123:0.007466:0.007100:0.005630:0.013143:0.012950:0.013143:0.003848:0.011738:0.007466:0.006523:0.005619:0.015644:0.014316:0.010660:0.010660:0.005330:0.005632:0.007620:0.005713:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005619:0.012604:0.006042:0.005619:0.015644:0.014316:0.010660:0.010660:0.006388
expressing B-cell lymphoma with rituximab :@0.084242:0.674473:0.480461:0.674473:0.480461:0.658717:0.084242:0.658717:0.012508:0.009236:0.013123:0.005713:0.012508:0.007466:0.007466:0.003848:0.011738:0.012950:0.005003:0.011045:0.006388:0.012450:0.012508:0.003848:0.003848:0.005003:0.003848:0.010314:0.018049:0.013123:0.011738:0.012604:0.018049:0.013143:0.005003:0.015990:0.003848:0.006523:0.011738:0.005003:0.005792:0.003848:0.006523:0.011699:0.009236:0.003848:0.018049:0.013143:0.013123:0.005330
leads to a modest response rate.  Radio-:@0.084242:0.690824:0.475156:0.690824:0.475156:0.675068:0.084242:0.675068:0.003848:0.012508:0.013143:0.013181:0.007466:0.008486:0.006523:0.012604:0.008486:0.013143:0.008486:0.018049:0.012604:0.013181:0.012508:0.007466:0.006523:0.008486:0.005711:0.012508:0.007466:0.013123:0.012604:0.011738:0.007466:0.012508:0.008486:0.005792:0.013143:0.006523:0.012508:0.005330:0.005330:0.003144:0.011680:0.013143:0.013181:0.003848:0.012604:0.006388
immunotherapy of B-cell  lymphoma in-:@0.084242:0.707175:0.475148:0.707175:0.475148:0.691420:0.084242:0.691420:0.003848:0.018049:0.018049:0.011699:0.011738:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.012546:0.012604:0.006042:0.012546:0.011045:0.006388:0.012450:0.012508:0.003848:0.003848:0.005330:0.007231:0.003848:0.010314:0.018049:0.013123:0.011738:0.012604:0.018049:0.013143:0.012546:0.003848:0.011738:0.006388
volves complexing of a therapy radionu-:@0.084242:0.723527:0.475171:0.723527:0.475171:0.707771:0.084242:0.707771:0.010660:0.012604:0.003848:0.010660:0.012508:0.007466:0.007909:0.012450:0.012604:0.018049:0.013123:0.003848:0.012508:0.009236:0.003848:0.011738:0.012950:0.007895:0.012604:0.006042:0.007893:0.013143:0.007909:0.006523:0.011738:0.012508:0.005792:0.013133:0.013123:0.010314:0.007909:0.005792:0.013143:0.013181:0.003848:0.012604:0.011738:0.011699:0.006388
clide to  a  monoclonal  antibody  against :@0.084242:0.739878:0.480488:0.739878:0.480488:0.724122:0.084242:0.724122:0.012450:0.003848:0.003848:0.013181:0.012508:0.009390:0.006523:0.012604:0.005330:0.004049:0.013143:0.005330:0.004051:0.018049:0.012604:0.011738:0.012604:0.012450:0.003848:0.012604:0.011738:0.013143:0.003848:0.005330:0.004041:0.013143:0.011738:0.006523:0.003848:0.013123:0.012604:0.013181:0.010314:0.005330:0.004049:0.013143:0.012950:0.013143:0.003848:0.011738:0.007466:0.006523:0.005330
CD20. Binding of a monoclonal antibody :@0.084242:0.756229:0.480447:0.756229:0.480447:0.740473:0.084242:0.740473:0.015644:0.014316:0.010660:0.010660:0.005330:0.007408:0.011045:0.003848:0.011738:0.013181:0.003848:0.011738:0.012950:0.007408:0.012604:0.006042:0.007408:0.013143:0.007408:0.018049:0.012604:0.011738:0.012604:0.012450:0.003848:0.012604:0.011722:0.013143:0.003848:0.007408:0.013143:0.011738:0.006523:0.003848:0.013123:0.012604:0.013181:0.010314:0.005330
to CD20 causes tumour-cell killing via dif-:@0.084242:0.772580:0.475142:0.772580:0.475142:0.756825:0.084242:0.756825:0.006523:0.012604:0.007241:0.015644:0.014316:0.010660:0.010660:0.007254:0.012450:0.013143:0.011699:0.007466:0.012508:0.007466:0.007254:0.006523:0.011699:0.018049:0.012604:0.011699:0.005792:0.006388:0.012450:0.012508:0.003848:0.003848:0.007239:0.009660:0.003848:0.003848:0.003848:0.003848:0.011738:0.012950:0.007254:0.010660:0.003848:0.013143:0.007254:0.013181:0.003848:0.006042:0.006388
ferent  immunological mechanisms, in-:@0.084242:0.788932:0.475156:0.788932:0.475156:0.773176:0.084242:0.773176:0.006042:0.012508:0.005709:0.012508:0.011738:0.006523:0.005330:0.012479:0.003848:0.018049:0.018049:0.011699:0.011738:0.012604:0.003848:0.012604:0.012950:0.003848:0.012450:0.013143:0.003848:0.017818:0.018049:0.012508:0.012450:0.011738:0.013143:0.011738:0.003848:0.007466:0.018049:0.007466:0.005330:0.017818:0.003848:0.011738:0.006388
cluding apoptosis, antibody-dependent :@0.084242:0.805283:0.480482:0.805283:0.480482:0.789527:0.084242:0.789527:0.012450:0.003848:0.011699:0.013181:0.003848:0.011738:0.012950:0.014047:0.013143:0.013123:0.012604:0.013123:0.006523:0.012604:0.007466:0.003848:0.007466:0.005330:0.014047:0.013143:0.011738:0.006523:0.003848:0.013123:0.012604:0.013181:0.010314:0.006388:0.013181:0.012508:0.013123:0.012508:0.011738:0.013181:0.012508:0.011738:0.006523:0.005330
cell-mediated cytotoxicity and com-:@0.084242:0.821634:0.475152:0.821634:0.475152:0.805878:0.084242:0.805878:0.012450:0.012508:0.003848:0.003848:0.006388:0.018049:0.012508:0.013181:0.003848:0.013143:0.006523:0.012508:0.013181:0.021378:0.012450:0.010314:0.006523:0.012604:0.006523:0.012604:0.009236:0.003848:0.012450:0.003848:0.006523:0.010314:0.021378:0.013143:0.011738:0.013181:0.021378:0.012450:0.012604:0.018049:0.006388
plement-dependent cytotoxicity. When :@0.084242:0.837985:0.480490:0.837985:0.480490:0.822230:0.084242:0.822230:0.013123:0.003848:0.012508:0.018049:0.012508:0.011738:0.006523:0.006388:0.013181:0.012508:0.013123:0.012508:0.011738:0.013181:0.012508:0.011738:0.006523:0.016106:0.012450:0.010314:0.006523:0.012604:0.006523:0.012604:0.009225:0.003848:0.012450:0.003848:0.006523:0.010314:0.005330:0.016106:0.018473:0.011738:0.012508:0.011738:0.005330
MAbs are labelled with a therapeutic ra-:@0.084242:0.854337:0.475156:0.854337:0.475156:0.838581:0.084242:0.838581:0.017684:0.014239:0.013123:0.007466:0.007433:0.013143:0.005713:0.012508:0.007431:0.003848:0.013143:0.013123:0.012508:0.003848:0.003848:0.012508:0.013181:0.007447:0.015990:0.003848:0.006523:0.011738:0.007433:0.013143:0.007435:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.012508:0.011699:0.006523:0.003848:0.012450:0.007429:0.005792:0.013143:0.006388
dionuclide, a combination of immunologi-:@0.084242:0.870688:0.475167:0.870688:0.475167:0.854932:0.084242:0.854932:0.013181:0.003848:0.012604:0.011738:0.011699:0.012450:0.003848:0.003848:0.013181:0.012508:0.005330:0.004907:0.013143:0.004907:0.012450:0.012604:0.018049:0.013123:0.003848:0.011738:0.013143:0.006523:0.003848:0.012604:0.011738:0.004895:0.012604:0.006042:0.004895:0.003848:0.018049:0.018049:0.011699:0.011738:0.012604:0.003848:0.012604:0.012950:0.003848:0.006388
cal and radiobiological cytotoxicity leads :@0.084242:0.887039:0.480463:0.887039:0.480463:0.871283:0.084242:0.871283:0.012450:0.013143:0.003848:0.006292:0.013143:0.011738:0.013181:0.006292:0.005792:0.013143:0.013181:0.003848:0.012604:0.013123:0.003848:0.012604:0.003848:0.012604:0.012950:0.003848:0.012450:0.013143:0.003848:0.006292:0.012450:0.010314:0.006523:0.012604:0.006523:0.012604:0.009236:0.003848:0.012450:0.003848:0.006523:0.010314:0.006292:0.003848:0.012508:0.013143:0.013181:0.007466:0.005330
to better tumour-killing than either alone.:@0.084242:0.903390:0.464722:0.903390:0.464722:0.887635:0.084242:0.887635:0.006523:0.012604:0.005330:0.013123:0.012508:0.006523:0.006523:0.012508:0.005792:0.005330:0.006523:0.011699:0.018049:0.012604:0.011699:0.005792:0.006388:0.009660:0.003848:0.003848:0.003848:0.003848:0.011738:0.012950:0.005330:0.006523:0.011738:0.013143:0.011738:0.005330:0.012508:0.003848:0.006523:0.011738:0.012508:0.005792:0.005330:0.013143:0.003848:0.012604:0.011738:0.012508:0.005330
Y-90 ibritumomab tiuxetan  (Zevalin) is :@0.102426:0.919742:0.480470:0.919742:0.480470:0.903986:0.102426:0.903986:0.011392:0.006388:0.010660:0.010660:0.012027:0.003848:0.013123:0.005792:0.003848:0.006523:0.011699:0.018049:0.012604:0.018049:0.013143:0.013123:0.012027:0.006523:0.003848:0.011699:0.009236:0.012508:0.006523:0.013143:0.011738:0.005330:0.006685:0.007100:0.009236:0.012508:0.010660:0.013143:0.003848:0.003848:0.011738:0.007100:0.012027:0.003848:0.007466:0.005330
presently the only commercially available :@0.084242:0.936093:0.480463:0.936093:0.480463:0.920337:0.084242:0.920337:0.013123:0.005715:0.012508:0.007466:0.012508:0.011738:0.006523:0.003848:0.010314:0.005965:0.006523:0.011738:0.012508:0.005954:0.012604:0.011738:0.003848:0.010314:0.005965:0.012450:0.012604:0.018049:0.018049:0.012508:0.005650:0.012450:0.003848:0.013143:0.003848:0.003848:0.010314:0.005965:0.013143:0.010660:0.013143:0.003848:0.003848:0.013143:0.013123:0.003848:0.012508:0.005330
radio-immunotherapy agent and is  indi-:@0.523643:0.096014:0.914544:0.096014:0.914544:0.080259:0.523643:0.080259:0.005792:0.013143:0.013181:0.003848:0.012604:0.006388:0.003848:0.018049:0.018049:0.011699:0.011738:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.010391:0.013143:0.012950:0.012508:0.011738:0.006523:0.010391:0.013143:0.011738:0.013181:0.010391:0.003848:0.007466:0.005330:0.005072:0.003848:0.011738:0.013181:0.003848:0.006388
cated in patients with rituximab-relapsed :@0.523643:0.112485:0.919884:0.112485:0.919884:0.096729:0.523643:0.096729:0.012450:0.013143:0.006523:0.012508:0.013181:0.007851:0.003848:0.011738:0.007851:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.007851:0.015990:0.003848:0.006523:0.011738:0.007851:0.005792:0.003848:0.006523:0.011699:0.009236:0.003848:0.018049:0.013143:0.013123:0.006388:0.005717:0.012508:0.003848:0.013143:0.013123:0.007466:0.012508:0.013181:0.005330
or  -refractory  CD20+ follicular non-Hodg-:@0.523643:0.128955:0.914552:0.128955:0.914552:0.113199:0.523643:0.113199:0.012604:0.005792:0.005330:0.003277:0.006388:0.005713:0.012508:0.006042:0.005792:0.013143:0.012450:0.006523:0.012604:0.005792:0.010314:0.005330:0.003277:0.015644:0.014316:0.010660:0.010660:0.011661:0.008621:0.006042:0.012604:0.003848:0.003848:0.003848:0.012450:0.011699:0.003848:0.013143:0.005792:0.008621:0.011738:0.012604:0.011738:0.006388:0.013143:0.012604:0.013181:0.012941:0.006388
kin’s lymphoma. It may be used as a first-:@0.523643:0.145425:0.914550:0.145425:0.914550:0.129669:0.523643:0.129669:0.009660:0.003848:0.011738:0.006754:0.007466:0.006639:0.003848:0.010314:0.018049:0.013123:0.011738:0.012604:0.018049:0.013143:0.005330:0.006629:0.004349:0.006523:0.006633:0.018049:0.013143:0.010314:0.006639:0.013123:0.012508:0.006637:0.011699:0.007466:0.012508:0.013181:0.006635:0.013143:0.007466:0.006641:0.013143:0.006637:0.004686:0.004686:0.005792:0.007466:0.006523:0.006388
line agent in other CD20+ B-cell lympho-:@0.523643:0.161896:0.914541:0.161896:0.914541:0.146140:0.523643:0.146140:0.003848:0.003848:0.011738:0.012508:0.008043:0.013143:0.012950:0.012508:0.011738:0.006523:0.008043:0.003848:0.011738:0.008043:0.012604:0.006523:0.011738:0.012508:0.005792:0.008032:0.015644:0.014316:0.010660:0.010660:0.011661:0.008043:0.011045:0.006388:0.012450:0.012508:0.003848:0.003848:0.008043:0.003848:0.010314:0.018049:0.013123:0.011738:0.012604:0.006388
mas.:@0.523643:0.178366:0.567631:0.178366:0.567631:0.162610:0.523643:0.162610:0.018049:0.013143:0.007466:0.005330
Contra-indications include::@0.523643:0.211307:0.775795:0.211307:0.775795:0.195551:0.523643:0.195551:0.015644:0.012604:0.011738:0.006523:0.005792:0.013143:0.006388:0.003848:0.011738:0.013181:0.003848:0.012450:0.013143:0.006523:0.003848:0.012604:0.011738:0.007466:0.005330:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.012508:0.005330
n   :@0.523636:0.224824:0.546445:0.224824:0.546445:0.216383:0.523636:0.216383:0.009762:0.003566:0.005914:0.003566
Pregnancy and continuing :@0.542878:0.227943:0.798008:0.227943:0.798008:0.212187:0.542878:0.212187:0.011392:0.005709:0.012508:0.012950:0.011738:0.013143:0.011738:0.012450:0.010314:0.005330:0.013143:0.011738:0.013181:0.005330:0.012450:0.012604:0.011738:0.006523:0.003848:0.011738:0.011699:0.003848:0.011738:0.012950:0.005330
breastfeeding:@0.542878:0.244413:0.674131:0.244413:0.674131:0.228657:0.542878:0.228657:0.013123:0.005715:0.012508:0.013143:0.007466:0.006523:0.006042:0.012508:0.012508:0.013181:0.003848:0.011738:0.012950
n   :@0.523636:0.257768:0.546445:0.257768:0.546445:0.249327:0.523636:0.249327:0.009762:0.003566:0.005914:0.003566
Known hypersensitivity to any :@0.542878:0.260887:0.820181:0.260887:0.820181:0.245131:0.542878:0.245131:0.011372:0.011738:0.012604:0.015990:0.011738:0.005330:0.011738:0.010314:0.013123:0.012508:0.005792:0.007466:0.012508:0.011738:0.007466:0.003848:0.006523:0.003848:0.010660:0.003848:0.006523:0.010314:0.005330:0.006523:0.012604:0.005330:0.013143:0.011738:0.010314:0.005330
component of the therapy agent:@0.542878:0.277357:0.854952:0.277357:0.854952:0.261601:0.542878:0.261601:0.012450:0.012604:0.018049:0.013123:0.012604:0.011738:0.012508:0.011738:0.006523:0.005330:0.012604:0.006042:0.005330:0.006523:0.011738:0.012508:0.005330:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.013143:0.012950:0.012508:0.011738:0.006523
n   :@0.523636:0.290712:0.546445:0.290712:0.546445:0.282272:0.523636:0.282272:0.009762:0.003566:0.005914:0.003566
Patients <18 years old:@0.542878:0.293831:0.743846:0.293831:0.743846:0.278075:0.542878:0.278075:0.011392:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330:0.011661:0.010660:0.010660:0.005330:0.010314:0.012508:0.013143:0.005792:0.007466:0.005330:0.012604:0.003848:0.013181
n   :@0.523636:0.307184:0.546445:0.307184:0.546445:0.298744:0.523636:0.298744:0.009762:0.003566:0.005914:0.003566
Poor bone-marrow reserve, WBC <1500/:@0.542878:0.310303:0.914532:0.310303:0.914532:0.294547:0.542878:0.294547:0.011392:0.012604:0.012604:0.005792:0.005303:0.013123:0.012604:0.011738:0.012508:0.006388:0.018040:0.013143:0.005792:0.005711:0.012604:0.015990:0.005317:0.005713:0.012508:0.007466:0.012508:0.005792:0.010660:0.012508:0.005330:0.005315:0.018473:0.011045:0.015644:0.005330:0.011661:0.010660:0.010660:0.010660:0.010660:0.008409
µl, platelets <100 000/µL:@0.542878:0.326773:0.762627:0.326773:0.762627:0.311018:0.542878:0.311018:0.011084:0.003848:0.005330:0.005330:0.013123:0.003848:0.013143:0.006523:0.012508:0.003848:0.012508:0.006523:0.007466:0.005330:0.011661:0.010660:0.010660:0.010660:0.005330:0.010660:0.010660:0.010660:0.008409:0.011084:0.008890
n   :@0.523636:0.340128:0.546445:0.340128:0.546445:0.331688:0.523636:0.331688:0.009762:0.003566:0.005914:0.003566
>25% bone-marrow infiltration by :@0.542878:0.343247:0.852154:0.343247:0.852154:0.327492:0.542878:0.327492:0.011661:0.010660:0.010660:0.014913:0.005330:0.013123:0.012604:0.011738:0.012508:0.006388:0.018049:0.013143:0.005792:0.005707:0.012604:0.015990:0.005330:0.003848:0.011738:0.004686:0.004686:0.003848:0.006523:0.005792:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330:0.013123:0.010314:0.005330
lymphoma cells on bone-marrow :@0.542878:0.359718:0.857170:0.359718:0.857170:0.343962:0.542878:0.343962:0.003848:0.010314:0.018049:0.013123:0.011738:0.012604:0.018049:0.013143:0.005330:0.012450:0.012508:0.003848:0.003848:0.007466:0.005330:0.012604:0.011738:0.005330:0.013123:0.012604:0.011738:0.012508:0.006388:0.018049:0.013143:0.005792:0.005702:0.012604:0.015990:0.005330
biopsy:@0.542878:0.376188:0.603357:0.376188:0.603357:0.360432:0.542878:0.360432:0.013123:0.003848:0.012604:0.013123:0.007466:0.010314
n   :@0.523636:0.389545:0.546445:0.389545:0.546445:0.381104:0.523636:0.381104:0.009762:0.003566:0.005914:0.003566
Previous bone-marrow or stem-cell :@0.542878:0.392664:0.869714:0.392664:0.869714:0.376908:0.542878:0.376908:0.011392:0.005709:0.012508:0.010660:0.003848:0.012604:0.011699:0.007466:0.005330:0.013123:0.012604:0.011738:0.012508:0.006388:0.018049:0.013143:0.005792:0.005705:0.012604:0.015990:0.005330:0.012604:0.005792:0.005330:0.007466:0.006523:0.012508:0.018049:0.006388:0.012450:0.012508:0.003848:0.003848:0.005330
transplantation:@0.542878:0.409134:0.683771:0.409134:0.683771:0.393378:0.542878:0.393378:0.006523:0.005792:0.013143:0.011738:0.007466:0.013123:0.003848:0.013143:0.011738:0.006523:0.013143:0.006523:0.003848:0.012604:0.011738
The following must be ensured  :@0.523636:0.442075:0.815689:0.442075:0.815689:0.426319:0.523636:0.426319:0.008197:0.011738:0.012508:0.005330:0.006042:0.012604:0.003848:0.003848:0.012604:0.015990:0.003848:0.011738:0.012950:0.005330:0.018049:0.011699:0.007466:0.006523:0.005330:0.013123:0.012508:0.005330:0.012508:0.011738:0.007466:0.011699:0.005688:0.012508:0.013181:0.005330:0.005330
before a patient is considered for :@0.523636:0.458545:0.839600:0.458545:0.839600:0.442789:0.523636:0.442789:0.013123:0.012508:0.006042:0.012604:0.005709:0.012508:0.005330:0.013143:0.005330:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.005330:0.003848:0.007466:0.005330:0.012450:0.012604:0.011738:0.007466:0.003848:0.013181:0.012508:0.005705:0.012508:0.013181:0.005330:0.006042:0.012604:0.005792:0.005330
radio-immunotherapy::@0.523636:0.475015:0.733051:0.475015:0.733051:0.459259:0.523636:0.459259:0.005792:0.013143:0.013181:0.003848:0.012604:0.006388:0.003848:0.018049:0.018049:0.011699:0.011738:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330
n   :@0.523636:0.488377:0.546445:0.488377:0.546445:0.479937:0.523636:0.479937:0.009762:0.003566:0.005914:0.003566
CD20 positivity on :@0.542878:0.491497:0.713251:0.491497:0.713251:0.475741:0.542878:0.475741:0.015644:0.014316:0.010660:0.010660:0.005330:0.013123:0.012604:0.007466:0.003848:0.006523:0.003848:0.010660:0.003848:0.006523:0.010314:0.005330:0.012604:0.011738:0.005330
immunohistochemical staining:@0.542878:0.507967:0.825665:0.507967:0.825665:0.492211:0.542878:0.492211:0.003848:0.018049:0.018049:0.011699:0.011738:0.012604:0.011738:0.003848:0.007466:0.006523:0.012604:0.012450:0.011738:0.012508:0.018049:0.003848:0.012450:0.013143:0.003848:0.005330:0.007466:0.006523:0.013143:0.003848:0.011738:0.003848:0.011738:0.012950
n   :@0.523636:0.521322:0.546445:0.521322:0.546445:0.512881:0.523636:0.512881:0.009762:0.003566:0.005914:0.003566
Check for correct indication and for :@0.542878:0.524441:0.884725:0.524441:0.884725:0.508685:0.542878:0.508685:0.015644:0.011738:0.012508:0.012450:0.009660:0.005330:0.006042:0.012604:0.005792:0.005330:0.012450:0.012604:0.005792:0.005682:0.012508:0.012450:0.006523:0.005330:0.003848:0.011738:0.013181:0.003848:0.012450:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330:0.013143:0.011738:0.013181:0.005330:0.006042:0.012604:0.005792:0.005330
absence of any contra-indication:@0.542878:0.540911:0.857203:0.540911:0.857203:0.525155:0.542878:0.525155:0.013143:0.013123:0.007466:0.012508:0.011738:0.012450:0.012508:0.005330:0.012604:0.006042:0.005330:0.013143:0.011738:0.010314:0.005330:0.012450:0.012604:0.011738:0.006523:0.005792:0.013143:0.006388:0.003848:0.011738:0.013181:0.003848:0.012450:0.013143:0.006523:0.003848:0.012604:0.011738
n   :@0.523636:0.554266:0.546445:0.554266:0.546445:0.545826:0.523636:0.545826:0.009762:0.003566:0.005914:0.003566
Life expectancy greater than three :@0.542878:0.557385:0.876037:0.557385:0.876037:0.541629:0.542878:0.541629:0.008890:0.003848:0.006042:0.012508:0.005330:0.012508:0.009236:0.013123:0.012508:0.012450:0.006523:0.013143:0.011738:0.012450:0.010314:0.005330:0.012950:0.005700:0.012508:0.013143:0.006523:0.012508:0.005792:0.005330:0.006523:0.011738:0.013143:0.011738:0.005330:0.006523:0.011738:0.005688:0.012508:0.012508:0.005330
months, Karnofsky index >70%:@0.542878:0.573855:0.819238:0.573855:0.819238:0.558099:0.542878:0.558099:0.018049:0.012604:0.011738:0.006523:0.011738:0.007466:0.005330:0.005330:0.011372:0.013143:0.006177:0.011738:0.012604:0.006042:0.007466:0.009660:0.010314:0.005330:0.003848:0.011738:0.013181:0.012508:0.009236:0.005330:0.011661:0.010660:0.010660:0.014913
Pre-therapy  imaging  with  Indium-111 ibri-:@0.523636:0.606796:0.914534:0.606796:0.914534:0.591040:0.523636:0.591040:0.011392:0.005709:0.012508:0.006388:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.002888:0.003848:0.018049:0.013143:0.012950:0.003848:0.011738:0.012950:0.005330:0.002892:0.015990:0.003848:0.006523:0.011738:0.005330:0.002892:0.004349:0.011738:0.013181:0.003848:0.011699:0.018049:0.006388:0.010660:0.010660:0.010660:0.008236:0.003848:0.013123:0.005792:0.003848:0.006388
tumomab to demonstrate bio-distribution :@0.523636:0.623266:0.919872:0.623266:0.919872:0.607510:0.523636:0.607510:0.006523:0.011699:0.018049:0.012604:0.018049:0.013143:0.013123:0.007468:0.006523:0.012604:0.007466:0.013181:0.012508:0.018049:0.012604:0.011738:0.007466:0.006523:0.005792:0.013143:0.006523:0.012508:0.007460:0.013123:0.003848:0.012604:0.006388:0.013181:0.003848:0.007466:0.006523:0.005792:0.003848:0.013123:0.011699:0.006523:0.003848:0.012604:0.011738:0.005330
of the agent,  which used to  be manda-:@0.523636:0.639737:0.914559:0.639737:0.914559:0.623981:0.523636:0.623981:0.012604:0.006042:0.008332:0.006523:0.011738:0.012508:0.008332:0.013143:0.012950:0.012508:0.011738:0.006523:0.005330:0.005330:0.002986:0.015990:0.011738:0.003848:0.012450:0.011738:0.008332:0.011699:0.007466:0.012508:0.013181:0.008332:0.006523:0.012604:0.005330:0.002992:0.013123:0.012508:0.008332:0.018049:0.013143:0.011738:0.013181:0.013143:0.006388
tory, is no longer mandatory prior to insti-:@0.523636:0.656207:0.914541:0.656207:0.914541:0.640451:0.523636:0.640451:0.006523:0.012604:0.005792:0.010314:0.005330:0.007231:0.003848:0.007466:0.007254:0.011738:0.012604:0.007235:0.003848:0.012604:0.011738:0.012950:0.012508:0.005792:0.007231:0.018049:0.013143:0.011738:0.013181:0.013143:0.006523:0.012604:0.005792:0.010314:0.007237:0.013123:0.005792:0.003848:0.012604:0.005792:0.007235:0.006523:0.012604:0.007237:0.003848:0.011738:0.007466:0.006523:0.003848:0.006388
tution  of  therapy with  Zevalin.  Zevalin is :@0.523636:0.672677:0.919879:0.672677:0.919879:0.656921:0.523636:0.656921:0.006523:0.011699:0.006523:0.003848:0.012604:0.011738:0.005330:0.004907:0.012604:0.006042:0.005330:0.004916:0.006523:0.011738:0.012508:0.005792:0.013133:0.013123:0.010314:0.010256:0.015990:0.003848:0.006523:0.011738:0.005330:0.004915:0.009236:0.012508:0.010660:0.013143:0.003848:0.003860:0.011738:0.005330:0.005330:0.004911:0.009236:0.012508:0.010660:0.013143:0.003848:0.003848:0.011738:0.010256:0.003848:0.007466:0.005330
administered as an intravenous infusion :@0.523636:0.689148:0.919899:0.689148:0.919899:0.673392:0.523636:0.673392:0.013143:0.013181:0.018049:0.003848:0.011738:0.003848:0.007466:0.006523:0.012508:0.005719:0.012508:0.013181:0.011757:0.013143:0.007466:0.011757:0.013143:0.011738:0.011757:0.003848:0.011738:0.006523:0.005792:0.013143:0.010660:0.012508:0.011738:0.012604:0.011699:0.007466:0.011757:0.003848:0.011738:0.006042:0.011699:0.007466:0.003848:0.012604:0.011738:0.005330
after  infusion  of  cold  rituximab to  block :@0.523636:0.705618:0.919885:0.705618:0.919885:0.689862:0.523636:0.689862:0.013143:0.006042:0.006523:0.012508:0.005792:0.005330:0.004851:0.003848:0.011738:0.006042:0.011699:0.007466:0.003848:0.012604:0.011738:0.005330:0.004857:0.012604:0.006042:0.005330:0.004857:0.012450:0.012604:0.003848:0.013181:0.005330:0.004859:0.005792:0.003848:0.006523:0.011699:0.009236:0.003848:0.018049:0.013143:0.013123:0.010198:0.006523:0.012604:0.005330:0.004851:0.013123:0.003848:0.012604:0.012450:0.009660:0.005330
CD20 expressed of  normal circulating B-:@0.523636:0.722088:0.914540:0.722088:0.914540:0.706332:0.523636:0.706332:0.015644:0.014316:0.010660:0.010660:0.009198:0.012508:0.009236:0.013123:0.005711:0.012508:0.007466:0.007466:0.012508:0.013181:0.009198:0.012604:0.006042:0.005330:0.003858:0.011738:0.012604:0.006317:0.018049:0.013143:0.003848:0.009198:0.012450:0.003848:0.005659:0.012450:0.011699:0.003848:0.013143:0.006523:0.003848:0.011738:0.012950:0.009198:0.011045:0.006388
cells and in the  spleen.  Zevalin is a pure :@0.523636:0.738558:0.919910:0.738558:0.919910:0.722803:0.523636:0.722803:0.012450:0.012508:0.003848:0.003848:0.007466:0.008428:0.013143:0.011738:0.013181:0.008428:0.003848:0.011738:0.008428:0.006523:0.011738:0.012508:0.005330:0.003086:0.007466:0.013123:0.003848:0.012508:0.012508:0.011738:0.005330:0.005330:0.003088:0.009236:0.012508:0.010660:0.013143:0.003848:0.003848:0.011738:0.008428:0.003848:0.007466:0.008428:0.013143:0.008428:0.013123:0.011699:0.005713:0.012508:0.005330
beta-emitting radionuclide and its admin-:@0.523636:0.755029:0.914553:0.755029:0.914553:0.739273:0.523636:0.739273:0.013123:0.012508:0.006523:0.013143:0.006388:0.012508:0.018049:0.003848:0.006523:0.006523:0.003848:0.011738:0.012950:0.005780:0.005792:0.013143:0.013181:0.003848:0.012604:0.011738:0.011699:0.012450:0.003848:0.003848:0.013181:0.012508:0.005792:0.013143:0.011738:0.013181:0.005792:0.003848:0.006523:0.007466:0.005792:0.013143:0.013181:0.018049:0.003848:0.011738:0.006388
istration does not expose caregivers to sig-:@0.523636:0.771499:0.914543:0.771499:0.914543:0.755743:0.523636:0.755743:0.003848:0.007466:0.006523:0.005792:0.013143:0.006523:0.003848:0.012604:0.011738:0.004757:0.013181:0.012604:0.012508:0.007466:0.004757:0.011738:0.012604:0.006523:0.004753:0.012508:0.009236:0.013123:0.012604:0.007466:0.012508:0.004757:0.012450:0.013143:0.005713:0.012508:0.012950:0.003848:0.010660:0.012508:0.005792:0.007466:0.004762:0.006523:0.012604:0.004751:0.007466:0.003848:0.012950:0.006388
nificant radiation.:@0.523636:0.787969:0.686927:0.787969:0.686927:0.772213:0.523636:0.772213:0.011738:0.003848:0.004686:0.004686:0.012450:0.013143:0.011738:0.006523:0.005330:0.005792:0.013143:0.013181:0.003848:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330
The commonest immediate side effects :@0.541820:0.804440:0.919900:0.804440:0.919900:0.788684:0.541820:0.788684:0.008197:0.011738:0.012508:0.006504:0.012450:0.012604:0.018049:0.018049:0.012604:0.011738:0.012498:0.007466:0.006523:0.006523:0.003848:0.018049:0.018049:0.012508:0.013181:0.003848:0.013143:0.006523:0.012508:0.006523:0.007466:0.003848:0.013181:0.012508:0.006523:0.012508:0.006096:0.006042:0.012508:0.012450:0.006523:0.007466:0.005330
of Zevalin infusion include asthenia, nau-:@0.523636:0.820910:0.914526:0.820910:0.914526:0.805154:0.523636:0.805154:0.012604:0.006042:0.008120:0.009236:0.012508:0.010660:0.013143:0.003848:0.003848:0.011738:0.008120:0.003848:0.011738:0.006042:0.011699:0.007466:0.003848:0.012604:0.011738:0.008120:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.012508:0.008120:0.013143:0.007466:0.006523:0.011738:0.012508:0.011738:0.003848:0.013143:0.005330:0.008120:0.011738:0.013143:0.011699:0.006388
sea, chills and fever.:@0.523636:0.837380:0.710764:0.837380:0.710764:0.821624:0.523636:0.821624:0.007466:0.012508:0.013143:0.005330:0.005330:0.012450:0.011738:0.003848:0.003848:0.003848:0.007466:0.005330:0.013143:0.011738:0.013181:0.005330:0.006042:0.012508:0.010660:0.012508:0.004383:0.005330
The superiority of Zevalin over cold rituxi-:@0.541820:0.853851:0.914526:0.853851:0.914526:0.838095:0.541820:0.838095:0.008005:0.011545:0.012315:0.006542:0.007274:0.011507:0.012931:0.012315:0.005600:0.003656:0.012411:0.005600:0.003656:0.006331:0.010122:0.006542:0.012411:0.005850:0.006542:0.009044:0.012315:0.010468:0.012950:0.003656:0.003656:0.011545:0.006542:0.012411:0.010468:0.012315:0.005600:0.006542:0.012257:0.012411:0.003656:0.012989:0.006542:0.005600:0.003656:0.006331:0.011507:0.009044:0.003656:0.006388
mab was demonstrated in a phase III trial :@0.523636:0.870321:0.919899:0.870321:0.919899:0.854565:0.523636:0.854565:0.017857:0.012950:0.012931:0.007177:0.015798:0.012950:0.007274:0.007177:0.012989:0.012315:0.017857:0.012411:0.011545:0.007274:0.006331:0.005600:0.012950:0.006331:0.012315:0.012989:0.007177:0.003656:0.011545:0.007177:0.012950:0.007177:0.012931:0.011545:0.012950:0.007274:0.012315:0.007177:0.004156:0.004156:0.004156:0.007177:0.006331:0.005600:0.003656:0.012950:0.003852:0.005330
that randomised 143 patients with relapsed :@0.523636:0.886791:0.919854:0.886791:0.919854:0.871035:0.523636:0.871035:0.006331:0.011545:0.012950:0.006331:0.004387:0.005600:0.012950:0.011545:0.012989:0.012411:0.017857:0.003656:0.007274:0.012315:0.012989:0.004387:0.010468:0.010468:0.010468:0.004387:0.012931:0.012950:0.006331:0.003656:0.012315:0.011545:0.006331:0.007274:0.004387:0.015798:0.003656:0.006331:0.011545:0.004387:0.005521:0.012315:0.003656:0.012950:0.012931:0.007274:0.012315:0.013181:0.005330
or refractory low-grade follicular lympho-:@0.523636:0.903262:0.914563:0.903262:0.914563:0.887506:0.523636:0.887506:0.012411:0.005600:0.009794:0.005521:0.012315:0.005850:0.005600:0.012950:0.012257:0.006331:0.012411:0.005600:0.010122:0.009794:0.003656:0.012411:0.015798:0.006196:0.012758:0.005600:0.012950:0.012989:0.012315:0.009794:0.005850:0.012411:0.003656:0.003656:0.003656:0.012257:0.011507:0.003656:0.012950:0.005600:0.009794:0.003656:0.010122:0.017857:0.012931:0.011545:0.012411:0.006388
ma  or  transformed  CD20+,  transformed :@0.523636:0.919732:0.919893:0.919732:0.919893:0.903976:0.523636:0.903976:0.017857:0.012950:0.005330:0.007743:0.012411:0.005600:0.005330:0.007743:0.006331:0.005600:0.012950:0.011545:0.007274:0.005850:0.012411:0.006131:0.017857:0.012315:0.012989:0.005330:0.007743:0.015452:0.014124:0.010468:0.010468:0.011468:0.005138:0.005330:0.007743:0.006331:0.005600:0.012950:0.011545:0.007274:0.005850:0.012411:0.006131:0.017857:0.012315:0.013183:0.005330
non-Hodgkin’s lymphoma to either receive :@0.523636:0.936202:0.919891:0.936202:0.919891:0.920446:0.523636:0.920446:0.011545:0.012411:0.011545:0.006196:0.012950:0.012411:0.012989:0.012758:0.009467:0.003656:0.011545:0.006562:0.007274:0.005186:0.003656:0.010122:0.017857:0.012931:0.011545:0.012411:0.017857:0.012950:0.005186:0.006331:0.012411:0.005186:0.012315:0.003656:0.006331:0.011545:0.012315:0.005600:0.005186:0.005521:0.012315:0.012257:0.012315:0.003656:0.010468:0.012506:0.005330